USANA Health Sciences (NYSE:USNA) Upgraded by StockNews.com to “Strong-Buy” Rating

StockNews.com upgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Separately, DA Davidson upgraded USANA Health Sciences to a “hold” rating in a research report on Friday, December 20th.

USANA Health Sciences Stock Performance

USNA opened at $35.69 on Friday. The company has a fifty day moving average of $37.88 and a two-hundred day moving average of $39.94. The stock has a market capitalization of $680.25 million, a price-to-earnings ratio of 12.61, a PEG ratio of 1.25 and a beta of 0.89. USANA Health Sciences has a fifty-two week low of $31.44 and a fifty-two week high of $54.81.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.07. The firm had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same quarter in the previous year, the business earned $0.59 EPS. On average, equities research analysts forecast that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Safe Harbor Fiduciary LLC acquired a new stake in shares of USANA Health Sciences in the third quarter valued at approximately $30,000. KBC Group NV grew its holdings in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares in the last quarter. Centiva Capital LP purchased a new stake in USANA Health Sciences in the 3rd quarter valued at $213,000. BOKF NA increased its stake in shares of USANA Health Sciences by 99.4% in the 2nd quarter. BOKF NA now owns 5,526 shares of the company’s stock worth $250,000 after acquiring an additional 2,755 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of USANA Health Sciences during the 3rd quarter worth $250,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.